Stephens & Co. Downgrades Q2 Holdings to Equal-Weight, Lowers Price Target to $50

Stephens & Co. analyst Charles Nabhan downgrades Q2 Holdings (NYSE:QTWO) from Overweight to Equal-Weight and lowers the price target from $65 to $50.

byBenzinga Newsdesk

May 17, 2022

1 minute read

Stephens & Co. analyst Charles Nabhan downgrades Q2 Holdings (NYSE:QTWO) from Overweight to Equal-Weight and lowers the price target from $65 to $50.

Seres Therapeutics Q2 EPS $(0.53) Misses $(0.37) Estimate

By Bill Haddad

Today, 6:23 AM

Seres Therapeutics (NASDAQ:MCRB) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.37) by 43.24 percent. This is a 89.29 percent decrease over losses of $(0.28) per share

MCRB

National Security Correspondent Sasha Ingber At Newsy Tweets ‘Two Sources Familiar With U.S. Intelligence Say That Senior Officers In Russia’s Intel Community Are Getting Fed Up With Putin. There Are Indications Critics There Want To Replace Him With A…

By Benzinga Newsdesk

Today, 6:23 AM

https://twitter.com/SashaIngber/status/1573314026830024706

RSX

Lowe’s Raises FY22 Adj. EPS Guidance From $13.10-$13.60 To $13.65-$13.80, Sees FY22 Total Sales $97B-~$98B., Comparable Sales Flat To Down 1%

By Benzinga Newsdesk

Today, 6:23 AM

ull Year 2022 Outlook -- a 53-week Year (comparisons to full year 2021 -- a 52-week year) Total sales of approximately $97 – $98 billion, including the 53rd week 53rd week expected to

LOW

Theravance Biopharma, Inc. Highlights 2022 Accomplishments And 2023 Key Targets; Said Seeks To Achieve Non-GAAP1 Profitability By 2H 2023

By Charles Gross

Today, 6:23 AM

Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced its 2022 Accomplishments and 2023 Key Targets.

TBPH

Stephens & Co. Downgrades Q2 Holdings to Equal-Weight, Lowers Price Target to $50

Related Posts

Seres Therapeutics Q2 EPS $(0.53) Misses $(0.37) Estimate

National Security Correspondent Sasha Ingber At Newsy Tweets ‘Two Sources Familiar With U.S. Intelligence Say That Senior Officers In Russia’s Intel Community Are Getting Fed Up With Putin. There Are Indications Critics There Want To Replace Him With A…

Lowe’s Raises FY22 Adj. EPS Guidance From $13.10-$13.60 To $13.65-$13.80, Sees FY22 Total Sales $97B-~$98B., Comparable Sales Flat To Down 1%

Theravance Biopharma, Inc. Highlights 2022 Accomplishments And 2023 Key Targets; Said Seeks To Achieve Non-GAAP1 Profitability By 2H 2023